AbbVie's Epcoritamab Achieves Phase 3 Win in DLBCL Trial
ABBV sits 41% above its 52-week low of $184.63.
Summary
AbbVie's epcoritamab+lenalidomide combination met its primary endpoint in a Phase 3 trial for relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL), demonstrating strong progression-free survival benefits. This significant clinical win de-risks a key pipeline asset and moves it closer to potential regulatory approval and commercialization. Separately, AbbVie paid a $10M milestone to Nxera for progress in a neuro drug-discovery partnership, indicating advancement in that collaboration. This positive drug development news follows the company's recent $10.9 billion acquisition of Apogee Therapeutics to expand its immunology portfolio.
At the time of this announcement, ABBV was trading at $261.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $461.3B. The 52-week trading range was $184.63 to $261.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.